2022 年第三季度报告 证券代码：605077 证券简称：华康股份 浙江华康药业股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比 上年同期增 | 年初至报告期末 | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 638,433,649.52 | 39.78 | 1,588,402,057.81 | 33.71 | ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 2022 年第一季度报告 证券代码：605077 证券简称：华康股份 浙江华康药业股份有限公司 2022 年第一季度报告 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | | | 单位：元 币种：人民币 | | --- | --- | --- | | 项目 | 本报告期 | 本报告期比上年同期增减 | | | | 变动幅度(%) | | 营业收入 | 405,395,609.58 | 23.34 | | 归属于上市公司股东的净利润 | 50,288,429.20 | -2.21 | | 归属于上市公司股东的扣除非经常 性损益的净利润 | 40,513,025.7 ...

浙江华康药业股份有限公司 2021 年年度报告 1 / 192 2021 年年度报告 重要提示 三、 天健会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人陈德水、主管会计工作负责人余建明及会计机构负责人（会计主管人员）汪家 发声明：保证年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 2021 年年度报告 公司代码：605077 公司简称：华康股份 公司利润分配及公积金转增股本预案如下： 1、公司拟向全体股东每10股派发现金红利6元（含税），截至本公告披露日，公司总股本为 16,318.4万股，以此计算合计拟派发现金红利9,791.04万元（含税）。 2、公司拟向全体股东每10股以资本公积金转增4股。以公司总股本16,318.4万股为基数计算 ，本次资本公积金转增股本后，公司总股本为22,845.76万股。 本次利润分配及公积金转增股本预案尚需提交公司2021年年度股东大会审议。 六、 前瞻性陈述的风险声明 √适用 □不适用 本公司2021年年度报告涉及的公司未来计划、发展战略等前瞻性描述不构成公司对投资者的 实质承诺 ...

2021 年第三季度报告 证券代码：605077 证券简称：华康股份 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期 | | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | 比上年同 | 年初至报告期末 | | | | | 期增减变 | | 增减变动幅度 | | | | 动幅度(%) | | (%) | | 营业收入 | 456,751,486.90 | 62.46 | 1,187,930,064.38 | 20.20 | | 归属于上市公司股东的 | 67,988,426.97 | 40.51 | 183,696,697.91 | -21.46 | | 净利润 | | | | | | 归属于上市公司股东的 扣除非经常性损益的净 | 54,965,755.42 | 17.89 | 156,919,482.90 | -28.45 | | 利润 | | | | | | 经营活动产生的现金流 | 不适用 | 不适用 | 75,843,441.43 | -69.62 | 浙江华康药业股份有限公司 ...

2021 年半年度报告 公司代码：605077 公司简称：华康股份 浙江华康药业股份有限公司 2021 年半年度报告 1/157 2021 年半年度报告 重要提示 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本公司2021年半年度报告涉及的公司未来计划、发展战略等前瞻性描述不构成公司对投资者 的实质承诺，敬请投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 公司已在本报告中详细描述了可能存在的风险，敬请查阅本报告第三节"管理层讨论与分析" 中"可能面对的风险"部分的内容。 十一、 其他 □适用 √不适用 2/157 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责 ...

2021 年第一季度报告 公司代码：605077 公司简称：华康股份 浙江华康药业股份有限公司 2021 年第一季度报告 1 / 20 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 6 | | 四、 | 附录 8 | 2021 年第一季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 | | | | 单位：元 币种：人民币 | | | --- | --- | --- | --- | --- | | | 本报告期末 | 上年度末 | 本报告期末比 | | | | | | 上年度末增减(%) | | | 总资产 | 2,790,743,338.12 | 1,429,680,665.26 | | 95.20 | | 归属于上市公司股东 | 2,365,717,559.91 | 939,521,622.79 | | 151.80 | | 的净资产 | | | | | | | 年初至报告期末 | 上年初至上年报告期末 | 比上年同期增减(%) | | | 经营活动产生的现金 | 3,329,315.77 | 81,267,064. ...

Dividend and Capital Structure - The company plans to distribute a cash dividend of 10 CNY per 10 shares, totaling 11.656 million CNY (including tax) based on a total share capital of 11.656 million shares[5]. - The company intends to increase its share capital by 4 shares for every 10 shares held, resulting in a new total share capital of 16.3184 million shares after the capital reserve conversion[5]. - The cash dividend policy remains unchanged during the reporting period, ensuring continuous and stable returns to shareholders[152]. - The company's profit distribution plan emphasizes a minimum cash distribution of 30% of the distributable profit if certain conditions are met, reflecting a commitment to shareholder returns[150]. Financial Performance - The company's operating revenue for 2020 was CNY 1,319,652,466.08, a decrease of 12.66% compared to 2019[24]. - The net profit attributable to shareholders for 2020 was CNY 307,167,236.37, representing an increase of 13.72% year-over-year[24]. - The basic earnings per share for 2020 was CNY 3.51, up 13.59% from CNY 3.09 in 2019[26]. - The total assets at the end of 2020 were CNY 1,429,680,665.26, an increase of 23.89% compared to the end of 2019[24]. - The net assets attributable to shareholders increased by 37.20% to CNY 939,521,622.79 at the end of 2020[24]. - The cash flow from operating activities for 2020 was CNY 335,241,828.39, a 19.17% increase from 2019[24]. - The company reported non-recurring gains of CNY 16,410,067.49 for 2020, compared to CNY 8,402,021.44 in 2019[30]. - The company’s total revenue for 2020 was approximately ¥199.38 million, representing a significant increase from ¥26.23 million in 2019, marking a growth of 658.5%[154]. - The net profit attributable to ordinary shareholders was approximately ¥270.11 million, compared to ¥52.45 million in the previous year, indicating a growth of 414.5%[154]. Audit and Compliance - The company has received a standard unqualified audit report from Tianjian Accounting Firm, ensuring the accuracy and completeness of the financial report[4]. - The company has confirmed that all board members attended the board meeting, ensuring accountability for the report's content[11]. - The company has made commitments regarding the accuracy and completeness of its prospectus, ensuring no false statements or omissions[158]. - The company’s board members and senior management have also pledged to uphold the integrity of the prospectus and will compensate investors for any losses due to inaccuracies[159]. - The company has committed to ensuring that any new business opportunities that may compete with its main business will be first offered to the company[173]. Market and Industry Position - The company focuses on the research, production, and sales of functional sugars such as xylitol, sorbitol, maltitol, and fructose syrup, positioning itself as a leading expert in the sugar alcohol industry[35]. - The company has established long-term cooperative relationships with well-known domestic and international food and beverage enterprises, with products sold in major markets across Europe, America, and Asia[35]. - The functional sugar alcohol industry shows stable demand with minimal cyclical characteristics, largely unaffected by macroeconomic fluctuations[45]. - The company has a comprehensive sales network covering most provinces and regions in China, transitioning from a B2B model to a combination of B2B and B2C[42]. - The global functional sugar alcohol market is projected to reach USD 3.268 billion by 2022, with a compound annual growth rate of 4.80% from 2017 to 2022[102]. Research and Development - The company employs a project responsibility system for R&D, focusing on continuous innovation of existing products and processes, as well as the development of new products[37]. - The company’s R&D investment reached RMB 65,033,606.88, a year-on-year increase of 20.89%, with 42 new patents granted, totaling 111 authorized patents[68]. - The company aims to strengthen its R&D capabilities by establishing a new research center and enhancing collaboration with universities and research institutions to drive innovation in product development[121]. - The company plans to focus on developing new products, including crystalline fructose and erythritol, to diversify its product offerings and reduce market volatility risks[120]. Risk Management - The company has detailed potential risks in the "Discussion and Analysis of Operating Conditions" section of the report[10]. - The company faces risks from potential price fluctuations of its main products due to increased competition and changes in market dynamics[135]. - The company is exposed to raw material price increase risks, particularly for starch, which could adversely affect profit levels[136]. - The company has significant transactions with its associate company, Yahua Bio, which could impact its performance if not managed properly[139]. Corporate Governance - The company has not violated decision-making procedures for external guarantees[8]. - The company has committed to not using its position to affect the company's independence or to illegally transfer funds or profits through related party transactions[175]. - The controlling shareholders and actual controllers of the company have committed not to interfere with the company's management and not to infringe on the company's interests[170]. Social Responsibility - The company has actively engaged in poverty alleviation efforts, contributing 500,000 RMB to support agricultural industrialization in Qing Shan Village, Zhejiang Province[196]. - The company plans to continue its focus on poverty alleviation and rural revitalization, aiming to consolidate poverty alleviation results and promote employment[197]. - During the COVID-19 pandemic, the company contributed 2.3 million yuan for local epidemic prevention efforts, with an additional 44,700 yuan donated by party members[199]. - The company organized multiple charitable activities, including visits to Qing Shan Village and a nursing home, contributing over 500,000 yuan to poverty alleviation efforts[200].